AAAAAA

   
Results: 1-9 |
Results: 9
A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2
Authors: Hagedorn, M Zilberberg, L Lozano, RM Cuevas, P Canron, X Redondo-Horcajo, M Gimenez-Gallego, G Bikfalvi, A
Citation: M. Hagedorn et al., A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2, FASEB J, 15(3), 2001, pp. 550-552
Solution structure and interaction with basic and acidic fibroblast growthfactor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity
Authors: Lozano, RM Redondo-Horcajo, M Jimenez, MA Zilberberg, L Cuevas, P Bikfalvi, A Rico, M Gimenez-Gallego, G
Citation: Rm. Lozano et al., Solution structure and interaction with basic and acidic fibroblast growthfactor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity, J BIOL CHEM, 276(38), 2001, pp. 35723-35734
Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependentand -independent mechanisms
Authors: Auguste, P Gursel, DB Lemiere, S Reimers, D Cuevas, P Carceller, F Di Santo, JP Bikfalvi, A
Citation: P. Auguste et al., Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependentand -independent mechanisms, CANCER RES, 61(4), 2001, pp. 1717-1726
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
Authors: Bello, L Carrabba, G Giussani, C Lucini, V Cerutti, F Scaglione, F Landre, J Pluderi, M Tomei, G Villani, R Carroll, RS Black, PM Bikfalvi, A
Citation: L. Bello et al., Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo, CANCER RES, 61(20), 2001, pp. 7501-7506
Target molecules for anti-angiogenic therapy: from basic research to clinical trials
Authors: Hagedorn, M Bikfalvi, A
Citation: M. Hagedorn et A. Bikfalvi, Target molecules for anti-angiogenic therapy: from basic research to clinical trials, CR R ONC H, 34(2), 2000, pp. 89-110
Neural and angiogenic defects in eyes of transgenic mice expressing a dominant-negative FGF receptor in the pigmented cells
Authors: Rousseau, B Dubayle, D Sennlaub, F Jeanny, JC Costet, P Bikfalvi, A Javerzat, S
Citation: B. Rousseau et al., Neural and angiogenic defects in eyes of transgenic mice expressing a dominant-negative FGF receptor in the pigmented cells, EXP EYE RES, 71(4), 2000, pp. 395-404
Role of fibroblast growth factor-2 in tumor angiogenesis.
Authors: Bikfalvi, A
Citation: A. Bikfalvi, Role of fibroblast growth factor-2 in tumor angiogenesis., PATH BIOL, 47(4), 1999, pp. 364-367
Fibroblast growth factor receptors participate in the control of mitogen-activated protein kinase activity during nerve growth factor-induced neuronal differentiation of PC12 cells
Authors: Chevet, E Lemaitre, G Janjic, N Barritault, D Bikfalvi, A Katinka, MD
Citation: E. Chevet et al., Fibroblast growth factor receptors participate in the control of mitogen-activated protein kinase activity during nerve growth factor-induced neuronal differentiation of PC12 cells, J BIOL CHEM, 274(30), 1999, pp. 20901-20908
Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action
Authors: Jouan, V Canron, X Alemany, M Caen, JP Quentin, G Plouet, J Bikfalvi, A
Citation: V. Jouan et al., Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action, BLOOD, 94(3), 1999, pp. 984-993
Risultati: 1-9 |